Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELCNASDAQ:EUDANASDAQ:FTRENASDAQ:SBC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$12.11-3.6%$10.76$7.58▼$19.77$458.56M0.37291,141 shs115,413 shsEUDAEUDA Health$3.71+9.8%$3.73$2.48▼$6.30$137.84M-0.0283,331 shs100,182 shsFTREFortrea$5.91-5.7%$5.25$3.97▼$28.41$534.86M1.591.87 million shs2.99 million shsSBCSBC Medical Group$4.43-1.1%$3.93$2.62▼$12.50$459.00M1.3561,642 shs80,333 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity0.00%-7.20%+15.11%+20.74%-19.27%EUDAEUDA Health0.00%+7.85%-6.08%-1.07%+53.94%FTREFortrea0.00%+11.93%+24.42%-38.82%-76.20%SBCSBC Medical Group0.00%-6.14%+27.30%+35.89%+442,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELCCelcuity1.9071 of 5 stars3.60.00.00.03.12.50.0EUDAEUDA Health0.3962 of 5 stars0.03.00.00.02.00.00.6FTREFortrea3.335 of 5 stars3.91.00.00.02.80.82.5SBCSBC Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.17Buy$30.80154.34% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/AFTREFortrea 1.86Reduce$15.00153.81% UpsideSBCSBC Medical Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EUDA, FTRE, SBC, and CELC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/2/2025FTREFortreaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$7.004/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/10/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$12.00 ➝ $6.004/9/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$5.48 per shareN/AEUDAEUDA Health$4.01M34.36N/AN/A($0.30) per share-12.37FTREFortrea$2.69B0.20$0.94 per share6.28$19.58 per share0.30SBCSBC Medical Group$197.94M2.32$0.09 per share49.20($1.68) per share-2.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$63.78M-$3.03N/AN/AN/AN/A-62.66%-39.78%8/13/2025 (Estimated)EUDAEUDA Health-$10.04MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)FTREFortrea-$3.40M-$8.79N/A4.621.78-10.99%2.00%0.80%8/11/2025 (Estimated)SBCSBC Medical Group$340KN/A0.000.79N/AN/A-11.59%-7.05%6/17/2025 (Estimated)Latest EUDA, FTRE, SBC, and CELC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SBCSBC Medical Group$0.11$0.21+$0.10$0.21$51.52 million$47.33 million5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/A3/28/2025Q4 2024SBCSBC Medical Group$0.17$0.18+$0.01$0.06$56.34 million$57.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AFTREFortreaN/AN/AN/AN/AN/ASBCSBC Medical GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity0.6510.3510.36EUDAEUDA HealthN/A0.13N/AFTREFortrea0.741.181.18SBCSBC Medical Group0.062.792.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%EUDAEUDA Health4.35%FTREFortreaN/ASBCSBC Medical Group60.82%Insider OwnershipCompanyInsider OwnershipCELCCelcuity15.77%EUDAEUDA HealthN/AFTREFortrea0.38%SBCSBC Medical Group89.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4037.87 million31.27 millionOptionableEUDAEUDA Health237.15 millionN/ANot OptionableFTREFortrea18,00090.50 million89.59 millionOptionableSBCSBC Medical GroupN/A103.61 million37.19 millionN/AEUDA, FTRE, SBC, and CELC HeadlinesRecent News About These CompaniesSBC Medical Group (NASDAQ:SBC) Shares Down 3.4% - Here's What HappenedJune 13 at 3:25 AM | marketbeat.comSBC Medical Group (NASDAQ:SBC) Stock Price Down 3.6% - Here's WhyJune 6, 2025 | marketbeat.comSBC Medical Group (NASDAQ:SBC) Shares Up 5.7% - Should You Buy?June 5, 2025 | marketbeat.comSBC Medical Group (NASDAQ:SBC) Trading Up 5.8% - Time to Buy?May 31, 2025 | marketbeat.comSBC Medical Group Holdings Incorporated Announces Participation in Upcoming Investor EventsMay 28, 2025 | quiverquant.comSBC Medical Announces Attendance at Upcoming Investor EventsMay 28, 2025 | globenewswire.comWhat is Zacks Small Cap's Estimate for SBC Q2 Earnings?May 24, 2025 | marketbeat.comQ3 EPS Estimates for SBC Medical Group Reduced by Sidoti CsrMay 23, 2025 | marketbeat.comSBC Medical Group Holdings First Quarter 2025 Earnings: EPS: US$0.21 (vs US$2.36 in 1Q 2024)May 17, 2025 | finance.yahoo.comIs It Too Late To Consider Buying SBC Medical Group Holdings Incorporated (NASDAQ:SBC)?May 16, 2025 | finance.yahoo.comSBC Medical Q1 Profit Rises 15 Pct Despite Revenue DipMay 16, 2025 | bernama.comSBC Medical Group Holdings Incorporated: SBC Medical Group Holdings Announces First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deSBC Medical Group Holdings Announces First Quarter 2025 Financial ResultsMay 15, 2025 | businesswire.comSBC Medical Group Holdings Announces Approval of Share Repurchase Program and Commencement of Share RepurchasesMay 15, 2025 | globenewswire.comWhy SBC Medical Group Holdings Incorporated’s (SBC) Stock Is Up 5.56%May 10, 2025 | aaii.comSBC Medical: Scalable Profits Undermined By Governance Overhang, Still Worth A LookMay 8, 2025 | seekingalpha.comSBC Medical Group Holdings, Inc. Purchases 5 BTCApril 14, 2025 | markets.businessinsider.comSBC Medical to Present at the Emerging Growth Conference on April 17, 2025April 9, 2025 | globenewswire.comSBC SBC Medical Group Holdings IncorporatedApril 5, 2025 | seekingalpha.comSBC: Recent Growth Measures Include Multi-Brand Strategy, Revised Pricing / Fee Structures, New Service OfferingsApril 2, 2025 | finance.yahoo.comSBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ ExpansionMarch 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEUDA, FTRE, SBC, and CELC Company DescriptionsCelcuity NASDAQ:CELC$12.11 -0.45 (-3.58%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$11.54 -0.57 (-4.75%) As of 06/13/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.EUDA Health NASDAQ:EUDA$3.71 +0.33 (+9.76%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$3.78 +0.08 (+2.02%) As of 06/13/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.Fortrea NASDAQ:FTRE$5.91 -0.36 (-5.74%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$5.90 -0.01 (-0.17%) As of 06/13/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.SBC Medical Group NASDAQ:SBC$4.45 -0.03 (-0.67%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
